Selecta Biosciences company info

What does Selecta Biosciences do?
Selecta Biosciences (NASDAQ:RNAC) is a biotechnology company focused on harnessing its proprietary immune tolerance platform, ImmTOR, aiming to mitigate unwanted immune responses. Their mission is to develop highly targeted therapies for rare and serious diseases. Operating at the cutting edge of immunology, Selecta Biosciences is leading the charge in creating novel treatments that enhance the efficacy and safety of biologics, gene therapies, and vaccines. Among its key projects, the company is advancing a pipeline of candidates addressing diseases such as chronic refractory gout, methylmalonic acidemia, and more. By pioneering the development of immune-modulating drugs, Selecta Biosciences seeks to bring life-changing treatments to patients with unmet medical needs, marking significant advancements in the realm of therapeutic biotechnology.
Selecta Biosciences company media
Company Snapshot

Is Selecta Biosciences a public or private company?

key
Ownership
Public

How many people does Selecta Biosciences employ?

people
Employees
27

What sector is Selecta Biosciences in?

pie chart
Sector
Health Care

Where is the head office for Selecta Biosciences?

location pin
Head Office
Watertown, United States

What year was Selecta Biosciences founded?

founded flag
Year Founded
2007
What does Selecta Biosciences specialise in?
/Immunotherapy Biologics /Gene Therapy /Synthetic Vaccine Particles /SVP Technology /Drug Design /Chronic Diseases
What are the products and/or services of Selecta Biosciences?
Overview of Selecta Biosciences offerings
SEL-212, a combination therapy designed to reduce uric acid levels in patients with chronic refractory gout.
ImmTOR platform, aimed at enhancing the efficacy and safety of biologic therapies, gene therapies, and vaccines.
Gene therapy programs leveraging the ImmTOR technology to potentially re-dose life-saving gene therapies.
Partnerships with high-profile companies for developing ImmTOR-enhanced therapeutic candidates in various diseases.
Innovative vaccine development program that utilizes ImmTOR technology to improve vaccine efficacy and reduce adverse reactions.
Research initiatives focused on expanding the therapeutic potential of the ImmTOR platform across a broader array of autoimmune diseases.
Who is in the executive team of Selecta Biosciences?
Selecta Biosciences leadership team
  • Dr. Carsten  Brunn Ph.D.
    Dr. Carsten Brunn Ph.D.
    President, CEO & Director
  • Mr. Blaine T. Davis
    Mr. Blaine T. Davis
    Chief Financial Officer
  • Dr. Metin  Kurtoglu M.D., Ph.D.
    Dr. Metin Kurtoglu M.D., Ph.D.
    Chief Technology Officer
  • Dr. Chris  Jewell Ph.D.
    Dr. Chris Jewell Ph.D.
    Chief Scientific Officer
  • Mr. Matthew  Bartholomae J.D.
    Mr. Matthew Bartholomae J.D.
    General Counsel & Secretary
  • Dr. Milos  Miljkovic M.D., Ph.D.
    Dr. Milos Miljkovic M.D., Ph.D.
    Chief Medical Officer
  • Dr. Emily  English Ph.D.
    Dr. Emily English Ph.D.
    SVP & Head of Manufacturing
  • Mr. Yi  Zhang Ph.D.
    Mr. Yi Zhang Ph.D.
    Senior Director of Technology